Toggle Main Menu Toggle Search

Open Access padlockePrints

National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: The Need for Pediatric-Specific Long-Term Follow-up Guidelines

Lookup NU author(s): Professor Roderick Skinner

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Existing standards for screening and management of late effects occurring in children who have undergone hematopoietic cell transplantation (HCT) include recommendations from pediatric cancer networks and consensus guidelines from adult-oriented transplantation societies applicable to all HCT recipients. Although these approaches have significant merit, they are not pediatric HCT-focused, and they do not address post-HCT challenges faced by children with complex nonmalignant disorders. In this article we discuss the strengths and weaknesses of current published recommendations and conclude that pediatric-specific guidelines for post-HCT screening and management would be beneficial to the long-term health of these patients and would promote late effects research in this field. Our panel of late effects experts also provides recommendations for follow-up and therapy of selected post-HCTorgan and endocrine complications in pediatric patients. Biol Mood Marrow Transplant 18: 334-347 (2012) (C) 2012 American Society for Blood and Marrow Transplantation


Publication metadata

Author(s): Pulsipher MA, Skinner R, McDonald GB, Hingorani S, Armenian SH, Cooke KR, Gracia C, Petryk A, Bhatia S, Bunin N, Nieder ML, Dvorak CC, Sung LL, Sanders JE, Kurtzberg J, Baker KS

Publication type: Article

Publication status: Published

Journal: Biology of Blood and Marrow Transplantation

Year: 2012

Volume: 18

Issue: 3

Pages: 334-347

Print publication date: 01/03/2012

Online publication date: 13/01/2012

Acceptance date: 11/01/2012

ISSN (print): 1083-8791

ISSN (electronic): 1523-6536

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.bbmt.2012.01.003

DOI: 10.1016/j.bbmt.2012.01.003


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
R01 CA112530-05National Institute of Health
U01HL069254National Institute of Health
Chimerix
Genzyme
Lance Armstrong Foundation
Sigma Tau Pharmaceuticals
Aldagen
Athersys
Otsuka America Pharmaceutical
St Baldrick's Foundation
1R13CA159788-01National Institute of Health

Share